Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Brings 25 years of global operations and supply chain experience to Piramal
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated
